Eton Pharmaceuticals Inc (ETON) - Total Liabilities
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has total liabilities worth $69.22 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Eton Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Eton Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Eton Pharmaceuticals Inc total assets.
Eton Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
C3 Ai Inc
NYSE:AI
|
USA | $162.52 Million |
|
CIE Automotive India Limited
NSE:CIEINDIA
|
India | Rs35.69 Billion |
|
Yangling Metron New Material Co Ltd
SHE:300861
|
China | CN¥701.24 Million |
|
Tecnoglass Inc
NYSE:TGLS
|
USA | $640.07 Million |
|
Hangzhou Shunwang Tech
SHE:300113
|
China | CN¥474.61 Million |
|
Henan Lingrui Pharmaceutical Co Ltd
SHG:600285
|
China | CN¥2.28 Billion |
|
Guizhou Aviation Technical Development Co Ltd
SHG:688239
|
China | CN¥3.10 Billion |
|
Hansol Chemica
KO:014680
|
Korea | ₩405.53 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Eton Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Eton Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eton Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Eton Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.96 Million | +27.59% |
| 2024-12-31 | $51.70 Million | +217.87% |
| 2023-12-31 | $16.26 Million | +36.07% |
| 2022-12-31 | $11.95 Million | +21.53% |
| 2021-12-31 | $9.84 Million | -7.70% |
| 2020-12-31 | $10.66 Million | +63.39% |
| 2019-12-31 | $6.52 Million | +222.23% |
| 2018-12-31 | $2.02 Million | +54.15% |
| 2017-12-31 | $1.31 Million | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more